Table 1.
General characteristics of participants.
| N = 15 | |
|---|---|
| Age (years) | 52.2 ± 6.88 |
| Sex (male:female) | 9:6 |
| Marital status | |
| Married | 15 |
| Education level | |
| Elementary school | 1 |
| Middle school | 2 |
| High school | 8 |
| University | 4 |
| Smoking | |
| Former smokers | 8 |
| Nonsmokers | 7 |
| Alcohol | |
| Nondrinkers | 9 |
| Drinkers | 4 |
| Abstainers | 2 |
| Height (cm) | 163.71 ± 7.63 |
| Weight (kg) | 67.09 ± 9.01 |
| BMI (kg/m2) | 25.10 ± 3.27 |
| Cancer type | |
| Acute myeloid leukemia | 5 |
| Diffuse large B-cell lymphoma | 3 |
| Angioimmunoblastic T-cell lymphoma | 2 |
| Acute lymphoblastic leukemia | 2 |
| Myelodysplastic syndrome | 1 |
| Follicular lymphoma | 1 |
| Multiple myeloma | 1 |
| Chemotherapy regimen | |
| BuCyE | 5 |
| BuFluATG | 7 |
| BuE | 1 |
| BuEAM | 1 |
| HD-MEL | 1 |
| Transplant | |
| Allogenic | 8 |
| Autologous | 7 |
| Isolation period (days) | 19.53 ± 1.77 |
| Number of telerehabilitation treatment | 8.67 ± 1.91 |
Values are mean ± standard deviation.
BMI = body mass index, BuCyE = busulfan, cyclophosphamide and etoposide, BuE = busulfan, etoposide, BuEAM = busulfan, etoposide, cytarabine, melphalan, BuFluATG = busulfan, fludarabine, and antithymocyteglobulin, MD-MEL = high-dose melphalan.